Aytu BioPharma (NASDAQ:AYTU) Downgraded by Wall Street Zen to “Hold”

Wall Street Zen cut shares of Aytu BioPharma (NASDAQ:AYTU) from a buy rating to a hold rating in a research report released on Friday morning.

Other research analysts have also recently issued reports about the company. Maxim Group cut their price target on Aytu BioPharma from $9.00 to $7.00 and set a “buy” rating for the company in a report on Thursday. Ascendiant Capital Markets raised their price objective on shares of Aytu BioPharma from $12.00 to $12.50 and gave the company a “buy” rating in a research report on Thursday. Finally, Lake Street Capital began coverage on shares of Aytu BioPharma in a research report on Tuesday, July 1st. They set a “buy” rating and a $8.00 target price on the stock. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $9.17.

Aytu BioPharma Stock Performance

NASDAQ:AYTU opened at $1.74 on Friday. The stock has a market capitalization of $17.24 million, a P/E ratio of -0.62 and a beta of 0.22. The company has a current ratio of 1.26, a quick ratio of 0.87 and a debt-to-equity ratio of 0.57. Aytu BioPharma has a 1 year low of $0.95 and a 1 year high of $2.82. The firm has a 50 day moving average of $2.34 and a 200-day moving average of $1.86.

Aytu BioPharma (NASDAQ:AYTU) last released its quarterly earnings results on Tuesday, September 23rd. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.24). Aytu BioPharma had a negative net margin of 20.43% and a positive return on equity of 13.77%. The business had revenue of $15.14 million for the quarter, compared to analyst estimates of $18.06 million.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. FNY Investment Advisers LLC bought a new position in shares of Aytu BioPharma in the 2nd quarter worth $78,000. Stonepine Capital Management LLC boosted its holdings in Aytu BioPharma by 13.8% during the first quarter. Stonepine Capital Management LLC now owns 463,721 shares of the company’s stock worth $556,000 after buying an additional 56,172 shares during the last quarter. Kanen Wealth Management LLC bought a new position in Aytu BioPharma during the second quarter worth about $1,250,000. Finally, AWM Investment Company Inc. acquired a new position in shares of Aytu BioPharma during the 2nd quarter worth about $1,351,000. Institutional investors and hedge funds own 33.49% of the company’s stock.

About Aytu BioPharma

Aytu Biopharma, Inc is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers.